Managed Access Programs for VAY736, Ianalumab
NCT07244289 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-03-23
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab
Conditions
- Primary Immune Thrombocytopenia
- Sjögren's Syndrome
Interventions
- DRUG
-
Patients receive ianalumab
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06958939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of Mirikizumab (LY3074828) in Healthy Participants
NCT02568423 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
NCT00619671 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Personalized Immunotherapeutic for Antibiotic-resistant Infection
NCT02508584 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
NCT06688435 ·Status: RECRUITING ·Phase: PHASE1
-
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
NCT02774239 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY3079514 in Healthy Participants
NCT02242903 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
NCT00744679 ·Status: COMPLETED ·Phase: PHASE4
-
Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients
NCT00138697 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
NCT04264884 ·Status: APPROVED_FOR_MARKETING
-
A Study of Galcanezumab in Healthy Participants.
NCT02836613 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Galcanezumab in Healthy Participants
NCT02576951 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
NCT00774462 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154 ·Status: RECRUITING ·Phase: PHASE1
-
Natalizumab in Inclusion Body Myositis (IBM)
NCT02483845 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of LY3016859 in Healthy Volunteers
NCT01545583 ·Status: COMPLETED ·Phase: PHASE1
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Rituxmab Versus IL-6 in Treating ILD
NCT05963048 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
AXER-204 in Participants With Chronic Spinal Cord Injury
NCT03989440 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
NCT06649695 ·Status: RECRUITING ·Phase: PHASE2
-
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
NCT07339540 ·Status: RECRUITING ·Phase: EARLY_PHASE1